For instance, the enhanced expression of FGFR1 and FGF2 causes lung cancer cells to escape from afatinib (a pan-EGFR kinase inhibitor) treatment, suggesting that the FGFR signaling pathway could compensate for the loss of the EGFR-driven signal12. The gene discussed is EGFR; the disease is lung carcinoma.